55P MOREL: Multicenter observational study on treatment and PD-L1 testing in patients (pts) with newly diagnosed stage IV NSCLC in Spain

First-line treatment of advanced NSCLC has undergone a great change in recent years. The aim of MOREL is to describe patterns of clinical management of newly diagnosed stage IV NSCLC pts without targetable mutations and to characterize PD-L1 testing in Spain. This is a multicenter, observational, retrospective study based on clinical records from 10 representative centers. Pts diagnosed in 2019 with stage IV NSCLC and no sensitizing mutations/translocations (EGFR, ALK, BRAF, ROS1) were included. Clinical management and PD-L1 diagnosis methods are described, according to demographic and clinicopathologic characteristics of the population. Two hundred ninety-seven patients were included. Overall, median age was 67 years (range: 37-89), 77.1% were male. ECOG 0, 1 or ≥2 was 27.8%, 46.4%, and 25.8%, respectively. 17.8 % had squamous NSCLC. 15.2% and 21.9% had liver and brain metastases, respectively. Data on autoimmune disease, comorbidities and systemic corticosteroids was also analyzed. PD-L1 test was performed in 287 pts (96.6%), 4.9% in centralized laboratory, with a median turnaround time of 5 days. The most used method was 22C3 pharmaDx kit (54.7%). PD-L1 TPS (<1%, 1-49% and ≥50%) account for 40.1%, 26.8%, and 32.1%, respectively.Table: 55PNDouble CT (Chemotherapy)Single agent CTIOCT + IOIO + IO%Overall treated population 26553.61.926.814.72.3Age groups ≤75 years 21854.11.424.3172.3 >75 years 4751.14.338.34.32.1Gender Male 20455.922712.72 Female 6145.91.626.221.33.3Smoking history Current/former smoker 23654.71.726.7142.1 Never smoked 2638.53.830.823.13.8ECOG 0-1 20952.2125.817.22.9 ≥2 5461.15.627.85.60NSCLC histological subtype Squamous 506822424 Non squamous 21549.81.927.417.72.3Brain Metastases Yes 5954.21.72218.63.4 No 20653.41.928.213.62.4PD-L1 TPS (%) <1 1007341211 1-49 7074.31.45.714.32.9 ≥50 8512.9076.57.13.5 Not evaluable 366.700033.3 Open table in a new tab The implementation of PD-L1 testing is feasible in the clinical practice and seems to guide treatment decisions with IO, according to the regulation in Spain.